trending Market Intelligence /marketintelligence/en/news-insights/trending/ebhrk99wfsae4lqvog0azq2 content esgSubNav
In This List

Celgene, Evotec enter collaboration to develop cancer treatments

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Celgene, Evotec enter collaboration to develop cancer treatments

Evotec AG and Celgene Corp. entered a collaboration to discover and develop therapies for cancer, with an initial focus on solid tumors.

Under the collaboration, Summit, N.J.-based Celgene will receive exclusive opt-in rights to license worldwide rights to all programs developed under the deal.

Hamburg-based Evotec will receive an up-front payment of $65 million and may be eligible to certain milestone payments and tiered royalties on licensed programs.

The collaboration will use Evotec's phenotypic screening platform to discover and develop therapies for various cancers.

The two companies, in 2016, also entered a collaboration to identify disease-modifying therapies for neurodegenerative diseases.